Fulton Breakefield Broenniman LLC Makes New $383,000 Investment in West Pharmaceutical Services, Inc. (NYSE:WST)

Fulton Breakefield Broenniman LLC purchased a new stake in shares of West Pharmaceutical Services, Inc. (NYSE:WSTFree Report) during the 4th quarter, HoldingsChannel.com reports. The institutional investor purchased 1,170 shares of the medical instruments supplier’s stock, valued at approximately $383,000.

Several other large investors have also recently added to or reduced their stakes in WST. Seilern Investment Management Ltd bought a new stake in West Pharmaceutical Services during the fourth quarter valued at $145,379,000. FMR LLC grew its position in shares of West Pharmaceutical Services by 199.4% during the 3rd quarter. FMR LLC now owns 595,775 shares of the medical instruments supplier’s stock valued at $178,828,000 after buying an additional 396,780 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in West Pharmaceutical Services by 21.8% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 683,350 shares of the medical instruments supplier’s stock worth $205,114,000 after acquiring an additional 122,361 shares during the period. Champlain Investment Partners LLC raised its stake in West Pharmaceutical Services by 29.7% during the third quarter. Champlain Investment Partners LLC now owns 444,000 shares of the medical instruments supplier’s stock worth $133,271,000 after acquiring an additional 101,710 shares during the period. Finally, DF Dent & Co. Inc. boosted its stake in West Pharmaceutical Services by 33.0% in the third quarter. DF Dent & Co. Inc. now owns 397,152 shares of the medical instruments supplier’s stock valued at $119,209,000 after acquiring an additional 98,564 shares during the period. 93.90% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on WST. UBS Group raised West Pharmaceutical Services from a “neutral” rating to a “buy” rating and raised their price target for the stock from $350.00 to $390.00 in a report on Thursday, December 12th. Citigroup initiated coverage on West Pharmaceutical Services in a report on Wednesday, January 8th. They set a “buy” rating and a $400.00 price target on the stock. Wolfe Research started coverage on shares of West Pharmaceutical Services in a research note on Friday, December 13th. They set a “peer perform” rating on the stock. Finally, Bank of America boosted their target price on West Pharmaceutical Services from $350.00 to $355.00 and gave the stock a “buy” rating in a research report on Friday, December 13th. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat, West Pharmaceutical Services has an average rating of “Moderate Buy” and an average price target of $430.20.

View Our Latest Stock Report on WST

West Pharmaceutical Services Stock Down 0.4 %

Shares of West Pharmaceutical Services stock opened at $343.67 on Wednesday. The firm has a market cap of $24.89 billion, a price-to-earnings ratio of 50.99, a P/E/G ratio of 18.59 and a beta of 1.00. The stock has a 50-day simple moving average of $329.87 and a 200-day simple moving average of $313.68. West Pharmaceutical Services, Inc. has a 52-week low of $265.00 and a 52-week high of $413.70. The company has a debt-to-equity ratio of 0.07, a current ratio of 3.00 and a quick ratio of 2.23.

About West Pharmaceutical Services

(Free Report)

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.

See Also

Want to see what other hedge funds are holding WST? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for West Pharmaceutical Services, Inc. (NYSE:WSTFree Report).

Institutional Ownership by Quarter for West Pharmaceutical Services (NYSE:WST)

Receive News & Ratings for West Pharmaceutical Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services and related companies with MarketBeat.com's FREE daily email newsletter.